Your account is not claimed yet. You can sign up with ORCID to claim your account.

Hervé Seitz

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 14

Top Venues

British journal of cancer

RNA biology

Nucleic acids research

Genome research

CNRS Délégation Languedoc-Roussillon

Université Paul Sabatier (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

CNRS Délégation Languedoc-Roussillon Oct 1o 2019

France

Directeur de recherche :: IGH

Education History

Université Paul Sabatier Sep 16o 2001 - Oct 25o 2004

France

PHD :: Life sciences

Publications

Sarah Janati-Idrissi, Mariana Roza de Abreu, Cervin Guyomar, Fernanda de Mello, Thaovi Nguyen, Nazim Mechkouri, Stéphanie Gay, Jérôme Montfort, Anne Alicia Gonzalez, Marzieh Abbasi, Jérôme Bugeon, Violette Thermes, Hervé Seitz, Julien Bobe
Looking for a needle in a haystack: de novo phenotypic target identification reveals Hippo pathway-mediated miR-202 regulation of egg production. Nucleic acids research (2023)
Élisabeth Houbron, Sophie Mockly, Sophia Rafasse, Nathalie Gros, Delphine Muriaux, Hervé Seitz
Biochemistry-informed design selects potent siRNAs against SARS-CoV-2. RNA biology 20 (1) (2023)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer (2022)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer 128 (3) (2022)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer 128 (3) (2022)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer (2022)
Sophie Mockly, Élisabeth Houbron, Hervé Seitz
A rationalized definition of general tumor suppressor microRNAs excludes miR-34a. Nucleic acids research 50 (8) (2022)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer 128 (3) (2022)
Sophie Mockly, Hervé Seitz
Synthetic miR-34a against solid tumours: a predictable failure. British journal of cancer (2022)
Jade Hebras, Virginie Marty, Jean Personnaz, Pascale Mercier, Nicolai Krogh, Henrik Nielsen, Marion Aguirrebengoa, Hervé Seitz, Jean-Phillipe Pradere, Bruno P Guiard, Jérôme Cavaille
Reassessment of the involvement of Snord115 in the serotonin 2c receptor pathway in a genetically relevant mouse model. eLife 9 (2020)
Patricia Richard, Shuang Feng, Yueh-Lin Tsai, Wencheng Li, Paola Rinchetti, Ubayed Muhith, Juan Irizarry-Cole, Katharine Stolz, Lionel A Sanz, Stella Hartono, Mainul Hoque, Saba Tadesse, Hervé Seitz, Francesco Lotti, Michio Hirano, Frédéric Chedin, Bin Tian, James L Manley
SETX (senataxin), the helicase mutated in AOA2 and ALS4, functions in autophagy regulation. Autophagy 17 (8) (2020)
Natalia Pinzón, Stéphanie Bertrand, Lucie Subirana, Isabelle Busseau, Hector Escrivá, Hervé Seitz
Functional lability of RNA-dependent RNA polymerases in animals. PLoS genetics 15 (2) (2019)
Hervé Seitz
Issues in current microRNA target identification methods. RNA biology 14 (7) (2017)
Natalia Pinzón, Blaise Li, Laura Martinez, Anna Sergeeva, Jessy Presumey, Florence Apparailly, Hervé Seitz
microRNA target prediction programs predict many false positives. Genome research 27 (2) (2016)

Hervé Seitz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hervé Seitz